文献速递心脑血管急症

四种决策工具在急诊科急性冠脉综合征早期诊断中的比较

Comparison of four decision aids for the early diagnosis of acute coronary syndromes in the emergency department.
PubMed 文献 · Emerg Med J · 2019-11-25
一句话结论在疑似急性冠脉综合征的急诊患者中,T-MACS可排除46.5%的患者且敏感性99.2%,HEART和TIMI评分诊断准确性较低。

该研究前瞻性纳入英格兰14个急诊科2015年2月至2017年6月期间疑似急性冠脉综合征且症状发作12小时内的患者,比较T-MACS、HEART、TIMI和EDACS四种决策工具及hs-cTnI单独使用对急性心肌梗死的诊断准确性。999例患者中132例(13.2%)发生急性心肌梗死。T-MACS的C统计量为0.96,HEART为0.78,TIMI为0.69。T-MACS可排除46.5%的患者且敏感性99.2%,EDACS可排除48.3%的患者但敏感性较低,差异无统计学意义。HEART和TIMI评分诊断准确性较低。

要点

  • T-MACS可排除46.5%的疑似急性冠脉综合征患者,对急性心肌梗死的敏感性为99.2%(95%CI 95.7%至100.0%)。
  • EDACS可排除48.3%的患者,敏感性96.2%(95%CI 92.2%至99.4%),与T-MACS的差异无统计学意义。
  • T-MACS、TIMI和HEART识别高危患者的阳性预测值分别为80.4%、51.9%和37.2%。
  • hs-cTnI<3 ng/L单独使用可排除28.8%的患者,敏感性99.2%(95%CI 95.9%至100.0%)。
  • HEART和TIMI评分的诊断准确性较低,C统计量分别为0.78和0.69,低于T-MACS的0.96。

适用人群与场景

  • 英格兰14个急诊科中,疑似急性冠脉综合征且在症状发作12小时内就诊的患者。

诊断标准与关键阈值

  • 目标疾病为经判定的急性心肌梗死诊断。
  • hs-cTnI采用定量下限切点3 ng/L。

研究设计与关键结果

  • 前瞻性纳入999例患者,其中132例(13.2%)发生急性心肌梗死。
  • T-MACS、HEART、TIMI的C统计量分别为0.96、0.78、0.69。
  • T-MACS、HEART、TIMI、EDACS及hs-cTnI<3 ng/L对急性心肌梗死的敏感性分别为99.2%(95%CI 95.7%至100.0%)、91.8%(95%CI 85.0%至96.2%)、97.5%(95%CI 92.9%至99.5%)、96.2%(95%CI 92.2%至99.4%)和99.2%(95%CI 95.9%至100.0%)。
  • 上述策略分别可排除46.5%、34.9%、19.4%、48.3%和28.8%的患者。
  • 识别高危患者的决策工具阳性预测值分别为T-MACS 80.4%、TIMI 51.9%、HEART 37.2%。
  • EDACS与T-MACS的敏感性差异无统计学意义。

证据类型、等级与局限

  • 证据类型:前瞻性诊断准确性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,T-MACS可在99.2%敏感性下排除46.5%的疑似急性冠脉综合征患者。
  • 作者认为,EDACS可排除48.3%的患者但敏感性较低,尽管差异无统计学意义。
  • HEART和TIMI评分在该研究中诊断准确性较低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To directly compare the diagnostic accuracy of four decision aids (Troponin-only Manchester Acute Coronary Syndromes (T-MACS), History, ECG, Age, Risk factors and Troponin (HEART), Thrombolysis in Myocardial Infarction (TIMI) and Emergency Department Assessment of Chest Pain (EDACS)) used to expedite the early diagnosis of acute coronary syndromes (ACS) in the ED.

METHODS: We prospectively included patients who presented to 14 EDs in England (February 2015 to June 2017) with suspected ACS within 12 hours of symptom onset. Data to enable evaluation of the T-MACS, HEART, TIMI and EDACS decision aids (without recalibration) were prospectively collected, blinded to patient outcome. We tested admission blood samples for high-sensitivity cardiac troponin I (hs-cTnI; Siemens ADVIA Centaur). Patients also underwent serial cardiac troponin testing over 3-12 hours. The target condition was an adjudicated diagnosis of acute myocardial infarction (AMI). We also evaluated the incidence of major adverse cardiac events (including death, AMI or coronary revascularisation) at 30 days. Diagnostic accuracy of each decision aid and hs-cTnI alone (using the limit of quantification cut-off, 3 ng/L) was evaluated by calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).

RESULTS: Of 999 included patients, 132 (13.2%) had AMI. C-statistics were 0.96 for T-MACS, 0.78 for HEART and 0.69 for TIMI. The sensitivities of T-MACS, HEART, TIMI, EDACS and hs-cTnI <3 ng/L for AMI were 99.2% (95% CI 95.7% to 100.0%), 91.8% (85.0% to 96.2%), 97.5% (92.9% to 99.5%), 96.2% (92.2% to 99.4%) and 99.2% (95.9% to 100.0%), respectively. The respective strategies would have ruled out 46.5%, 34.9%, 19.4%, 48.3% and 28.8% patients. PPVs for the decision aids that identify 'high-risk' patients were 80.4% (T-MACS), 51.9% (TIMI) and 37.2% (HEART).

CONCLUSIONS: In this study, T-MACS could rule out AMI in 46.5% patients with 99.2% sensitivity. EDACS could rule out AMI in 48.3% patients with lower sensitivity, although the difference was not statistically significant. The HEART and TIMI scores had lower diagnostic accuracy.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Body R, Morris N, Reynard C, et al. Comparison of four decision aids for the early diagnosis of acute coronary syndromes in the emergency department. Emerg Med J. 2019. PMID: 31767674. doi:10.1136/emermed-2019-208898

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。